Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
US Army
UBS
Daiichi Sankyo
McKesson
QuintilesIMS
Boehringer Ingelheim
Argus Health
Harvard Business School

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,132,089

« Back to Dashboard

Which drugs does patent 9,132,089 protect, and when does it expire?

Patent 9,132,089 protects ANDROGEL and is included in two NDAs.

Protection for ANDROGEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and nine patent family members in thirty-one countries.
Summary for Patent: 9,132,089
Title:Pharmaceutical composition and method for treating hypogonadism
Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.
Inventor(s): Dudley; Robert E. (Kenilworth, IL), Drouin; Dominique (Verrieres le Buisson, FR)
Assignee: BESINS HEALTHCARE INC. (Herndon, VA) UNIMED PHARMACEUTICALS, LLC (Abbott Park, IL)
Application Number:13/942,245
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,132,089

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ANDROGEL testosterone GEL, METERED;TRANSDERMAL 021015-003 Sep 26, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-002 Sep 7, 2012 AB2 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 AB2 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 021015-001 Feb 28, 2000 AB1 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 021015-002 Feb 28, 2000 AB1 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,132,089

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,004,092,494 ➤ Subscribe
6,503,894 Pharmaceutical composition and method for treating hypogonadism ➤ Subscribe
9,125,816 Pharmaceutical composition and method for treating hypogonadism ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,132,089

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 036970 ➤ Subscribe
Austria 429920 ➤ Subscribe
Austria 460939 ➤ Subscribe
Australia 2001285367 ➤ Subscribe
Australia 2001286995 ➤ Subscribe
Australia 2001290598 ➤ Subscribe
Australia 2003228314 ➤ Subscribe
Australia 2003277388 ➤ Subscribe
Australia 8536701 ➤ Subscribe
Australia 8699501 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
Healthtrust
Farmers Insurance
Johnson and Johnson
Cerilliant
Baxter
Covington
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot